Gain Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $55,180 | $140,108 | $164,994 |
| Operating income | -$18.7M | -$20.4M | -$22.3M | -$17.8M | -$13.8M |
| Operating expenses | $18.7M | $20.4M | $22.3M | $17.9M | $14.0M |
| Cash from operations | -$18.5M | -$18.9M | -$18.9M | -$14.7M | -$12.4M |
| Capital expenditure | — | $22,493 | $15,358 | $118,953 | $94,212 |
| Free cash flow | — | -$18.9M | -$18.9M | -$14.8M | -$12.5M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $22.8M | $12.1M | $18.6M | $24.1M | $39.0M |
| Total liabilities | $4.3M | $4.8M | $6.0M | $5.2M | $4.2M |
Shares outstanding 42.7M · Free float 95.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.